tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ACXP Stock Latest News

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
Press ReleasesAcurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
16d ago
ACXP
Acurx reports Q2 EPS (26c) vs (28c) last year
PremiumThe Fly
Acurx reports Q2 EPS (26c) vs (28c) last year
16d ago
ACXP
Acurx granted new patent for ibezapolstat to treat CDI
PremiumThe Fly
Acurx granted new patent for ibezapolstat to treat CDI
1M ago
ACXP
Acurx presents Phase 2 results of ibezapolstat in C. difficile Infection
PremiumThe Fly
Acurx presents Phase 2 results of ibezapolstat in C. difficile Infection
1M ago
ACXP
Acurx reports results from meeting with FDA regarding ibezapolstat
PremiumThe Fly
Acurx reports results from meeting with FDA regarding ibezapolstat
3M ago
ACXP
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
PremiumPress ReleasesAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
3M ago
ACXP
Acurx presents ibezapolstat Phase 2 clinical trial results in CDI
Premium
The Fly
Acurx presents ibezapolstat Phase 2 clinical trial results in CDI
4M ago
ACXP
Acurx price target lowered to $12 from $14 at H.C. Wainwright
Premium
The Fly
Acurx price target lowered to $12 from $14 at H.C. Wainwright
5M ago
ACXP
Acurx files common stock offering, no amount given
PremiumThe Fly
Acurx files common stock offering, no amount given
5M ago
ACXP
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
PremiumPress Releases
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
5M ago
ACXP
Acurx’s ibezapolstat granted end of Phase 2 meeting by FDA, EMA SME designation
PremiumThe Fly
Acurx’s ibezapolstat granted end of Phase 2 meeting by FDA, EMA SME designation
6M ago
ACXP
Acurx’s antibiotic candidate shows positive Phase 2b clinical cure data
PremiumThe Fly
Acurx’s antibiotic candidate shows positive Phase 2b clinical cure data
7M ago
ACXP
Acurx announces results from ibezapolstat Phase 2b clinical trial
PremiumThe FlyAcurx announces results from ibezapolstat Phase 2b clinical trial
7M ago
ACXP
Acurx price target raised by $1 at H.C. Wainwright, here’s why
Premium
The Fly
Acurx price target raised by $1 at H.C. Wainwright, here’s why
8M ago
ACXP
Acurx price target raised to $14 from $13 at H.C. Wainwright
Premium
The Fly
Acurx price target raised to $14 from $13 at H.C. Wainwright
8M ago
ACXP
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
PremiumPress Releases
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
9M ago
ACXP
Acurx reports Q3 EPS (24c), consensus (27c)
PremiumThe Fly
Acurx reports Q3 EPS (24c), consensus (27c)
9M ago
ACXP
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
10M ago
CD
ET
Acurx says Phase 2 ibezapolstat trial met primary objective
PremiumThe Fly
Acurx says Phase 2 ibezapolstat trial met primary objective
10M ago
ACXP
Acurx discontinues Phase 2b clinical trial of ibezapolstat
PremiumThe FlyAcurx discontinues Phase 2b clinical trial of ibezapolstat
11M ago
ACXP
Acurx price target lowered to $13 from $14 at H.C. Wainwright
Premium
The Fly
Acurx price target lowered to $13 from $14 at H.C. Wainwright
1y ago
ACXP
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
Premium
Press Releases
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
1y ago
ACXP

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >